Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.36 |
| ▸ | CNR2 | P34972 | 7/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 5/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4841026 | 0.88 | CNR2 (0.39) | CNR1CNR2TP53CRHR1MAPT | |
| SCHEMBL8444084 | 0.85 | CNR2 (0.35) | CNR1CNR2TP53CRHR1MAPT | |
| SCHEMBL4833058 | 0.85 | CNR1 (0.38) | CNR1CNR2 | |
| SCHEMBL4840849 | 0.82 | CNR1 (0.40) | CNR1CNR2TP53CRHR1MAPT | |
| SCHEMBL4841478 | 0.81 | DRD4 (0.41) | TP53CYP3A4 | |
| SCHEMBL4840644 | 0.78 | CNR1 (0.40) | CNR1CNR2TP53CRHR1MAPT | |
| SCHEMBL5607652 | 0.78 | CNR1 (0.40) | CNR1CNR2TP53CRHR1MAPT | |
| SCHEMBL4832926 | 0.78 | CNR1 (0.45) | CNR1CNR2TP53CRHR1MAPT | |
| SCHEMBL8261401 | 0.78 | CNR1 (0.45) | CNR1CNR2TP53CRHR1MAPT | |
| SCHEMBL4844544 | 0.77 | CRHR1 (0.45) | CNR1CNR2TP53CRHR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | claimed |
| US-7329658-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1592691-A1 | PYRAZOLO[1,5-A][1,3,5]TRIAZINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069837-A1 | PYRAZOLO`1,5-A!`1,3,5!TRIAZINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885TP53 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.